相似文献
1
One conclusion may hide another.
CMAJ. 2002 Aug 20;167(4):329, 331.
2
Hormone replacement therapy: a time for pause.
CMAJ. 2002 Aug 20;167(4):357-9.
3
Menopausal hormone replacement therapy.
Curr Womens Health Rep. 2003 Oct;3(5):410-7.
4
The arrogance of preventive medicine.
CMAJ. 2002 Aug 20;167(4):363-4.
5
The Women's Health Initiative. Implications for practice.
Adv Nurse Pract. 2002 Nov;10(11):53-5.
6
Good science or good marketing?
Altern Med Rev. 2002 Aug;7(4):274-5.
7
Observations and advertising: controversies in the prescribing of hormone replacement therapy.
Health Care Women Int. 2003 Dec;24(10):927-39. doi: 10.1080/07399330390244167.
8
Postmenopausal hormone therapy and informed consent: a call for common sense.
J Womens Health (Larchmt). 2005 Sep;14(7):592-4. doi: 10.1089/jwh.2005.14.592.
9
Making evidence-based decisions in medicine: (or more importantly) using evidence when the case doesn't quite fit.
Womens Health Issues. 2004 Jan-Feb;14(1):3-6. doi: 10.1016/j.whi.2003.12.003.
10
HRT, HERS, NIH, WHI: alphabet soup?
J Gend Specif Med. 2002 Nov-Dec;5(6):10-3.
本文引用的文献
1
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321.
2
Norethynodrel-mestranol (enovid) for prevention and treatment of the climacteric.
J Am Geriatr Soc. 1966 Oct;14(10):967-85. doi: 10.1111/j.1532-5415.1966.tb02880.x.
Zotero 插件